Fujisawa Pharmaceutical Company, Ltd.

Morita Iwami

Masanobu Kohsaka

Shigehiro Takase

Itsuo Uchida

Hitoshi Kojo

Masao Fukagawa

Ichiro Aramori

Hiroshi Imanaka

Masanori Okamoto

Tadaaki Komori

Kazuyoshi Umehara

Hiroshi Terano

Masashi Hashimoto

Takao Isogai

Michio Yamashita

Hiroki Ono

Motoaki Nishikawa

Mana Tsumura

Yosuke Ishitani

Masami Ezaki

Keizo Yoshida

Sumio Kiyoto

Kozo Ochi

Masanobu Konsaka

The present invention provides a process for producing 7-aminocephem compounds or salts thereof. 7-Aminocephem compounds are produced via microorganisms transformed with a vector containing a gene capable of converting a cephalosporin compound of the formula (II): ##STR1## to a 7-aminocephem compound of the formula (I): ##STR2##

Process for producing 7-aminocephem compound or salts thereof

A cephalosporin C acylase from Pseudomonas diminuta N-176 is characterized by its ability to catalyze the conversion of cephalosporin C, glutaryl 7-ACA, adipyl 7-ACA, succinyl 7-ACA, N-acetylcephalosporin, N-benzoylcephalosporin C and cephalothin into 7-aminocephalosporanic acid. The enzyme contains an .alpha.-subunit having a molecular weight of 26 kDA and a .beta.-subunit having a molecular weight of 58 kDa. A method for the recombinant production of the present cephalosporin C acylase in Escherichia coli is provided.

Cephalosporin C acylase

A GL-7ACA acylase having the following characteristics:

GL-7ACA acylase

A cephalosporin C acylase from Pseudomonas diminuta N-176 is disclosed as well as the recombinant production of this enzyme in E. coli. The enzyme is characterized by the ability to catalyze the conversion of cephalosporin C, gultaryl 7-ACA, apidyl 7-ACA, succinyl 7-ACA, N-acetylcephalosporin C, N-benzoylcephalosporin C, and cephalothin into 7-aminocephalosporanic acid and is composed of an .alpha.-subunit with a molecular weight of 26,000 daltons and a .beta.-subunit with a molecular weight of 58,000 daltons.

FR-900493 is a compound of molecular formula C.sub.20 H.sub.33 N.sub.5 O.sub.11 which may be recovered from Bacillus cultures, possesses antimicrobial activity, and may be used for the treatment and prevention of infectious diseases in humans and animals.

FR-900493 substance, a process for its production and a pharmaceutical

New nitro aliphatic compounds useful as antithrombotic and antihypertensing agents are disclosed.

Nitro aliphatic compounds, process for preparation thereof and use

The invention relates to a method for treatment of carcinoma or sarcoma tumor in mammals which comprises administering to said mammal an effective amount of a tetracyclo compound of the formula: ##STR1## in which R.sup.1 is formyl, protected formyl, hydroxymethyl, protected hydroxymethyl, arylaminomethyl, carboxy, protected carboxy, aryliminomethyl, hydroxyiminomethyl, alkoxyiminomethyl, acyloxyiminomethyl, semicarbazonomethyl or arylsemicarbazonomethyl,

Method of treating tumors using tetracyclo compounds

The invention relates to compounds of antihypertensive and antithrombotic activity of the formula or its pharmaceutically acceptable salt: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, or lower alkoxyphenyl,

Nitro aliphatic compounds and use thereof

New nitro aliphatic compounds and their pharmaceutically acceptable salts are disclosed.

New Nitro aliphatic compounds and their pharmaceutically acceptable salts are disclosed.

A biologically pure culture of Streptomyces sandaensis which is capable of producing an antitumor and antimicrobial compound, designated FR-900482 substance, is disclosed.

Biologically pure culture of Streptomyces sandaensis No. 6897

This invention relates to a biologically active WS-7739-A substance and a biologically active WS-7739-B substance which have pharmacological activities and are useful for the treatment of asthma, thrombosis and the alike.

WS 7739 substances, their preparation and pharmaceutical composition

New tetracyclo compounds of the formula: ##STR1## in which R.sup.1 is formyl, protected formyl, hydroxymethyl, protected hydroxymethyl, arylaminomethyl, carboxy, protected carboxy or substituted iminomethyl,

Tetracyclo compounds and a pharmaceutical composition containing the same

Novel compounds designated as WS 6049-A and WS 6049-B are disclosed, as well as compositions containing the compounds thereof, a method of treating microbial infections, a method of prolonging the survival time of the patient with lymphocytic leukemia by administering the compounds thereof, and a process for making the WS 6049 substances, are disclosed. As indicated above, the novel compounds have antimicrobial and antileukemic activities which make them useful against a variety of pathogenic microorganisms and leukemic tumors.

Growing community of inventors

Takarazuka, Japan

Morita Iwami